The addition of palbociclib to endocrine therapy was not associated with preventing disease recurrence in patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative early breast cancer, according to final results of the phase 3 PALLAS trial.
A recent analysis suggests transfeminine individuals were at a 40% greater risk of developing diabetes than their cisgender counterparts, but this increase in risk was not attributable to gender-affirming hormone therapy.
Daré Bioscience announces the US Food and Drug Administration has approved their clindamycin phosphate (Xaciato) vaginal gel for bacterial vaginosis.
COVIDmenses is recruiting participants for a study to examine potential effects of COVID-19 vaccination on menstrual health.
It is essential to expand access to all available, effective cervical cancer screening options for the most vulnerable populations. The targeted use of any particular screening modality in higher-risk populations is not supported by evidence-based guidelines; any effective screening is the priority.
The North American Society for Pediatric and Adolescent Gynecology (NASPAG) recently released a clinical opinion on how to diagnose and manage vulvar lichen sclerosus.
At AAGL’s 50th Global Congress on MIGS, Peter L. Rosenblatt, MD, and Cheryl B. Iglesia, MD, FACOG, debated the use of native tissue repair and transvaginal mesh in pelvic reconstructive surgery.
In a panel discussion at AAGL’s 50th Global Congress on MIGS, in Austin, Texas, Kimberly Kho, MD, MPH, along with Jessica Shepherd, MD, MBA, FACOG, and Craig Sobolewski, MD, discussed utilizing radiofrequency ablation for treatment of uterine fibroids.
“My hysteroscope is my stethoscope. I use it in every opportunity when the story doesn’t match,” Linda D. Bradley, MD, said during her presentation at AAGL’s 50th Global Congress on MIGS, “Office Hysteroscopy: Seeing is Believing. A Manifesto for Change.”
Gaby Moawad, MD, FACOG, spoke about the benefits of using AI for minimally invasive gynecologic surgery and its future potential in the specialty.
“If you want to provide comprehensive care, it is truly impossible as 1 person,” began Jean Uy-Kroh, MD, FACOG, director, Chronic Pelvic Pain Program at the Cleveland Clinic in Cleveland, Ohio, at AAGL’s 50th Global Congress on MIGS in Austin, Texas.
Results of a cross-sectional study detail characteristics among women with polycystic ovary syndrome (PCOS) who develop type 2 diabetes.
“Today, many of these cases are done as open surgery, including approximately 60% of all hysterectomies performed globally, despite the clear benefits of minimally invasive surgery, which includes fewer complications, a shorter hospital stay, and a faster return to normal activities,” Peron told Contemporary OB/GYN®.
The reality is that traditional laparoscopic surgery provides excellent outcomes, great surgical exposure, and the flexibility to tackle almost any clinical situation. As such it is a high bar to overcome—vNOTES is essentially single port vaginal surgery.
Optimization of care represents a priority and requires an understanding of etiology to effectively diagnose and treat.
Contemporary OB/GYN® held a panel discussion in September with 4 renowned minimally invasive gynecologic surgeons (MIGS) who discussed vaginal natural orifice transluminal endoscopic surgery (vNOTES).
Hologic is planning to launch its new global endometrial ablation device at the upcoming AAGL conference in November.
Age of first menarche has long been seen as a girl's start to puberty, but breast development may be a better fit.
In an analysis of SWAN data, investigators found changes in menstrual cycle length within the 5 years preceding a woman's final menstrual period was associated with changes in carotid intima-media thickness and brachial-ankle pulse wave velocity.
Barb Dehn, NP, discusses vaccine hesitancy, soy and estrogen receptors, and a hospital in Tanzania dedicated to improving women's health through quality health care and education in under-resourced communities.
Recurrent urinary tract infections (UTIs) place a large burden on women as they struggle to find the right remedies for this problem. According to guidelines, there is only 1 temporary cure for this condition and that is antibiotics. As more antibiotics are taken by this susceptible population, however, the bacteria can adapt and make recurrent UTI treatment in the future much more difficult.
Gloria A. Bachmann, MD, MMS sat down with Michael Krychman, MD, at the North American Menopause Society (NAMS) Annual Meeting to talk about telemedicine and her work providing trauma-informed care to women in prison.
At the North American Menopause Society's (NAMS) 2021 Annual Meeting, sexual health specialist Michael Krychman, MD sat down with Brooke Faught, NP to learn more about the Women's Institute for Sexual Health, her role on the Planning Committee, and her tips for talking trauma with patients.
Michael Krychman, MD, sat down with Alyssa Dweck, MD, gynecologist and Bonafide medical advisor to catch up at this year's North American Menopause Society (NAMS) Annual Meeting.
The FDA has granted priority review to a supplemental biologics license application for the use of cemiplimab-rwlc in the treatment of patients with recurrent or metastatic cervical cancer whose disease progressed on, or after, chemotherapy.
